Leukotriene receptor antagonists in the treatment of bronchial asthma
 [Consensus agreement "Bronchial Asthma and LEukoTriene receptor antagonists (BALET)"]
نویسندگان
چکیده
Under the auspices of Russian Association Allergists and Clinical Immunologists Pediatric Respiratory Society, an expert meeting "Leukotriene receptor antagonists in treatment bronchial asthma" was held. Asthma is a common non-communicable chronic disorder airways characterized by variable recurring symptoms, airflow obstruction, hyperresponsiveness, underlying inflammation. The creation widespread use inhaled corticosteroids (ICS) other innovative classes drugs for asthma has significantly affected ability to achieve control over course disease. Despite this, most European countries, more than half patients with have suboptimal disease [1]. In past decades, class leukotriene blockers which contributes suppression allergic inflammation been actively studied. majority studies confirm usefulness montelukast as monotherapy add-on therapy ICS mild moderate across all age groups [12-19,21-40]. However, experts note that practical medicine healthcare providers continue ask questions regarding effectiveness safety this medicines asthma. consensus document, considered it important provide unequivocal answer clinical practice several topical antileukotriene therapy.
منابع مشابه
Role of leukotriene receptor antagonists in asthma.
Asthma is a chronic inflammatory disease that affects >300 million people worldwide. However, inhaled corticosteroids (ICS), the gold standard therapy for persistent asthma, cannot suppress every component of airway inflammation and often fail to adequately penetrate the small airways in order completely suppress eosinophilia. Cysteinyl leukotrienes are important inflammatory factors that are i...
متن کامل195 The Impact of Administration of Leukotriene Receptor Antagonists, Pranlukast-EK to Infants with Bronchial Asthma
increased the time to first asthma deterioration thus decreasing the proportion of subjects experiencing asthma deterioration during the study (MF/F 1⁄4 16.5%; versus MF 1⁄4 28.2% [P 1⁄4 0.006]; versus F 1⁄4 44.7% [P , 0.001]; and vs placebo 1⁄4 45.7% [P , 0.001]). Mean FEV1 AUC0–12h over baseline at week 12 were MF/F 1⁄4 4.00 L · h; MF 1⁄4 2.53 L · h; F 1⁄4 3.83 L · h; and placebo 1⁄4 1.11 L ·...
متن کاملClinical evaluation of leukotriene receptor antagonists in preventing common cold-like symptoms in bronchial asthma patients.
BACKGROUND We investigated the possibility of preventing common cold-like symptoms as a previously unknown benefit of leukotriene receptor antagonists (LTRAs). METHODS A total of 279 adult patients with bronchial asthma referred to our hospital between June and December 2004 were retrospectively analyzed. Patients were divided into LTRA treated and untreated groups. Frequency of acute exacerb...
متن کاملLeukotriene receptor antagonists for the treatment of asthma.
Leukotriene receptor antagonists (LTRAs) are novel medications that provide symptom control in patients with persistent asthma. Current guidelines recommend the use of LTRAs as a treatment option for patients with mild-persistent asthma of at least 12 years of age. As illustrated by the results of controlled, multicenter clinical trials with zafirlukast and montelukast, as well as studies with ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rossijskij allergologi?eskij žurnal
سال: 2023
ISSN: ['1810-8830', '2686-682X']
DOI: https://doi.org/10.36691/rja7530